Blood Coagulation & Fibrinolysis最新文献

{"title":"Concurrence of prothrombin nonneutralizing antibody and factor XI neutralizing inhibitor in lupus anticoagulant positive patient.","authors":"Ju Hyeong Lee, Ja-Yoon Gu, Junshik Hong, Kwon-Wook Joo, Eun Young Lee, Hyun Kyung Kim","doi":"10.1097/MBC.0000000000001360","DOIUrl":"10.1097/MBC.0000000000001360","url":null,"abstract":"<p><p>Isolated prothrombin antibody or isolated factor XI inhibitor have been reported separately in lupus-anticoagulant positive patients. We report the first case of a lupus-anticoagulant positive patient that both simultaneously occurred. A 30-year-old man with a history of systemic lupus erythematosus was positive for lupus-anticoagulant. He exhibited significantly high bleeding score compared to previous reports of lupus-anticoagulant positive patients with isolated prothrombin or factor XI deficiency. Examination via one-stage clotting assays revealed decreased levels of both prothrombin and factor XI. Factor parallelism was proven for prothrombin but not for factor XI. The factor XI inhibitor was quantified at 2.1 Bethesda units in the Bethesda assay, and antiprothrombin nonneutralizing antibody tested positive in ELISA. This study suggests that the concurrence of prothrombin nonneutralizing antibody and factor XI neutralizing inhibitor can aggravate bleeding tendency synergistically in lupus-anticoagulant positive patient. Bethesda assay or ELISA may be considered depending on the factor-parallelism in one-stage clotting assay.</p>","PeriodicalId":8992,"journal":{"name":"Blood Coagulation & Fibrinolysis","volume":" ","pages":"130-133"},"PeriodicalIF":1.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143771348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing fondaparinux and low molecular weight heparin for thromboprophylaxis after hip and knee arthroplasty: a systematic review and meta-analysis.","authors":"Muhammad Hassan Waseem, Zain Ul Abideen, Nohela Rehman, Sarosh Ali, Esha Dilawar, Haseeb Javed Khan, Burhan Khalid, Muhammad Ansab, Sania Aimen, Areehah Zafar Masood","doi":"10.1097/MBC.0000000000001352","DOIUrl":"10.1097/MBC.0000000000001352","url":null,"abstract":"<p><p>Venous thromboembolism (VTE) remains a significant cause of perioperative morbidity and mortality despite the availability of prophylactic medications. There has been a debate about which thromboprophylaxis medication, Fondaparinux or low-molecular weight heparin (LMWH), is better after hip and knee arthroplasty. We have compared these two treatment regimens in our study. Electronic databases like PubMed, Cochrane, and ScienceDirect were searched from inception to August 2024. The weighted mean difference (WMD) for continuous outcomes and risk ratio (RR) for dichotomous outcomes were pooled using the Review Manager software version 5.4.1, and a random effects model was employed. The Newcastle-Ottawa Scale and Cochrane Risk of Bias Tool (ROB 2.0) were used to assess the quality of the included studies. Publication bias was evaluated visually through funnel plots and statistically through Egger's regression. GRADE assessment was used to analyze the certainty of evidence. A total of 17 studies, 9 Cohorts, and 8 Randomized controlled trials (RCTs) pooling a total of 74 499 patients were included in this meta-analysis. Fondaparinux showed a statistically significant reduction in the risk of VTE [0.59; 95% confidence interval (CI): [0.48, 0.71]; P  < 0.00001; I2  = 36%] and deep venous thrombosis (DVT) (RR = 0.75, 95% CI: [0.56, 1.00]; P  = 0.05; I2  = 68%) compared to LMWH. Major bleeding (RR = 2.06, 95% CI: [1.19, 3.57]; P  = 0.01; I2  = 43%), surgical site bleeding (RR = 1.67, 95% CI: [1.04, 2.66]; P  = 0.03; I2  = 9%), and postoperative transfusions (RR = 1.07, 95% CI: [1.02, 1.12]; P  = 0.004; I2  = 0%) were significantly higher in the Fondaparinux group. Symptomatic VTE, pulmonary embolism, mortality, and operating time showed no significant difference between the two groups. In conclusion, Fondaparinux is superior to LMWH in VTE and DVT prophylaxis. However, it is associated with an increased risk of major bleeding, surgical site bleeding, and postoperative transfusions.</p>","PeriodicalId":8992,"journal":{"name":"Blood Coagulation & Fibrinolysis","volume":" ","pages":"119-129"},"PeriodicalIF":1.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143699477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hemolysis detection accuracy on Stago sthemO 301.","authors":"Simone Denitto, Gian Luca Salvagno, Emmanuel J Favaloro, Giuseppe Lippi","doi":"10.1097/MBC.0000000000001359","DOIUrl":"https://doi.org/10.1097/MBC.0000000000001359","url":null,"abstract":"","PeriodicalId":8992,"journal":{"name":"Blood Coagulation & Fibrinolysis","volume":"36 4","pages":"134-135"},"PeriodicalIF":1.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143967460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association between the polymorphism of FXI c.539A>G and venous thromboembolism in the population of central china.","authors":"Na Liu, Yanyan You, Jingdi Liu, Liang Tang, Wei Zeng","doi":"10.1097/MBC.0000000000001368","DOIUrl":"https://doi.org/10.1097/MBC.0000000000001368","url":null,"abstract":"<p><strong>Background: </strong>Venous thromboembolism (VTE) has a genetic component that can differ significantly among populations. The genetic landscape of VTE in China, where incidence is rising, may harbor unique susceptibilities. This study aimed to examine the factor XI (FXI) c.539A>G polymorphism's role in VTE risk and its correlation with FXI levels among central Chinese VTE patients.</p><p><strong>Methods: </strong>We included 1748 VTE patients and 1819 matched controls, and extracted genomic DNA. Direct sequencing identified the FXI c.539A>G mutation in 50 patient samples. FXI antigen levels were quantified using ELISA, and bioinformatics evaluated the mutation's biological significance.</p><p><strong>Results: </strong>The FXI c.539A>G mutation occurred in three heterozygous individuals. It was more prevalent in VTE patients (2.26%) than controls (1.37%), with a significant odds ratio of 1.66 (95% CI: 1.16-2.37, P = 5.03 × 10-3). Patients with the mutation showed increased FXI antigen levels (16.76 ± 5.78 ng/ml) versus the wild-type (10.77 ± 4.98 ng/ml, P = 1.20 × 10-3), without affecting FXI activity (P = 0.57).</p><p><strong>Conclusion: </strong>The FXI c.539A>G variant is associated with VTE in central China, marked by elevated FXI antigen levels but not altered activity. This finding suggests that FXI c.539A>G may serve as a genetic marker for VTE risk. Further studies are needed to explore its role in early screening of VTE and gene-environment interactions.</p>","PeriodicalId":8992,"journal":{"name":"Blood Coagulation & Fibrinolysis","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143962366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing prediction of thrombosis associated with breast cancer using prechemotherapy hematologic and coagulation characteristics.","authors":"Regan Bucciol, Hannah Parente, Yousra Tera, E Claire Bunker, Aditi Kini, Brooke E Wilson, Mihaela Mates, Maha Othman","doi":"10.1097/MBC.0000000000001367","DOIUrl":"https://doi.org/10.1097/MBC.0000000000001367","url":null,"abstract":"<p><strong>Introduction: </strong>The applicability of venous thromboembolism (VTE) risk assessment models (RAMs), to breast cancer (BC) populations remains unclear. We aimed to compare the efficacy of current RAMs and examine the potential of additional hematologic parameters and thromboelastography (TEG); a point of care test, in improving VTE prediction in breast cancer (BC) patients.</p><p><strong>Methods: </strong>In this pilot study, female BC patients were recruited before chemotherapy and followed for 6-12 months for VTE. VTE risk was assessed using Khorana score, Vienna CATS, PROTECHT, COMPASS-CAT, New Vienna CATSCORE, MDACC CAT, and hypercoagulability status. TEG and hematologic parameters were analyzed, and a modified RAM was developed.</p><p><strong>Results: </strong>Among 47 patients, 5 (10.6%) developed VTE. PROTECHT was the strongest predictor [area under the curve (AUC) = 0.844], followed by Vienna CATS (AUC = 0.781). Adding immature granulocytes and red blood cell count to PROTECHT optimized prediction (AUC = 0.856).</p><p><strong>Conclusion: </strong>Incorporating hematologic parameters into PROTECHT may improve VTE risk prediction in BC patients, warranting further evaluation in larger studies.</p>","PeriodicalId":8992,"journal":{"name":"Blood Coagulation & Fibrinolysis","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143962495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Platelet secretion defects and increased CD63 expression in Hermansky-Pudlak syndrome\" a case report.","authors":"Massoumeh Shahbazi, Minoo Ahmadinejad","doi":"10.1097/MBC.0000000000001366","DOIUrl":"https://doi.org/10.1097/MBC.0000000000001366","url":null,"abstract":"<p><p>Hermansky-Pudlak syndrome (HPS) is an autosomal recessive disorder characterized by clinical features including oculocutaneous albinism (OCA) and bleeding diathesis due to platelet storage pool deficiency. In this article, we report a 12-year-old boy with recurrent epistaxis who was referred to the Iranian Blood Transfusion Organization (IBTO) reference coagulation laboratory for platelet function analysis. Based on the laboratory diagnostic tests in this study and the patient's clinical presentation, the probability of HPS type 2 is more likely.</p>","PeriodicalId":8992,"journal":{"name":"Blood Coagulation & Fibrinolysis","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143974330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hemostatic effects of combined Thymus vulgaris and Medicago sativa extracts: in silico and in vivo study.","authors":"Zahra Sadat Mashkani, Jafar Vatandoost, Toktam Hajjar, Mitra Kheirabadi","doi":"10.1097/MBC.0000000000001356","DOIUrl":"https://doi.org/10.1097/MBC.0000000000001356","url":null,"abstract":"<p><strong>Objective: </strong>This study aims to evaluate the hemostatic effects of combined extracts from Thymus vulgaris and Medicago sativa in an animal model, focusing on their impact on coagulation indices. We hypothesize that the combined extracts will modulate the extrinsic and intrinsic coagulation pathways, improving hemostasis.</p><p><strong>Methods: </strong>Thirty-two male NMRI mice were randomly assigned to four groups (n = 8): negative control (distilled water), 300 mg/kg/day M. sativa (MS300), 100 mg/kg/day T. vulgaris extract (TV100), and combined extracts (TV100 + MS300). After 14 days of treatment, blood samples were collected to measure prothrombin time (PT) and activated partial thromboplastin time (aPTT). Chemical analysis identified active compounds, and molecular docking studies were performed to assess their interaction with coagulation factor VIIa (FVIIa).</p><p><strong>Results: </strong>The treated groups showed significant changes in coagulation indices compared to the control. PT was significantly decreased (P < 0.05), and aPTT was significantly increased (P < 0.05) in the M. sativa, T. vulgaris, and combined extract groups. The combined extract showed the most significant effect. Computational analyses revealed that compounds like Scandenon and Vitamin E interacted with FVIIa, suggesting their role in modulating the extrinsic coagulation pathway. These compounds showed strong binding affinity to FVIIa.</p><p><strong>Conclusion: </strong>Combined extracts of T. vulgaris and M. sativa significantly influence coagulation, especially the extrinsic pathway. The presence of aromatic, hydroxyl, alcoholic, and phenolic groups in these compounds likely contributes to their interaction with coagulation factors. These findings support the potential development of plant-based hemostatic agents for clinical use.</p>","PeriodicalId":8992,"journal":{"name":"Blood Coagulation & Fibrinolysis","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143974847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel pathogenic variant in the fibrinogen gamma chain gene p.Glu275Lys causes congenital hypofibrinogenemia.","authors":"Miroslava Drotarova, Rosanna Asselta, Sonia Caccia, Ingrid Skornova, Jana Zolkova, Zuzana Kolkova, Dusan Loderer, Vladimir Podusel, Jan Stasko, Tomas Simurda","doi":"10.1097/MBC.0000000000001362","DOIUrl":"https://doi.org/10.1097/MBC.0000000000001362","url":null,"abstract":"<p><p>Congenital hypofibrinogenemia presents not only with bleeding, but also paradoxically with thrombosis. This heterogeneity of clinical phenotype complicates both diagnosis and management. The thrombotic phenotype is thought to arise from alterations in fibrin structure and stability, leading to abnormal clot formation and an increased risk of thrombosis. Coagulation assays, gene analysis, and protein modeling were utilized to elucidate the pathogenic variant. We highlight the pathophysiology of the novel missense variant in the FGG gene (c.823G/A, p.Glu275Lys), which causes mild hypofibrinogenemia and clinically manifests as an ischemic stroke. Protein modeling displays that the amino-acid substitution of glutamine with lysine at position 275 in mentioned missense variant causes local changes in the fibrinogen structure. The structural changes are mainly minor surface alterations and changes in physicochemical properties, which could potentially affect the recruitment of other proteins or lead to abnormal fibrin polymerization. This study provides novel insights into the pathophysiological mechanism, emphasizing the importance of molecular and structural analyses in understanding and managing atypical presentations of fibrinogen disorders.</p>","PeriodicalId":8992,"journal":{"name":"Blood Coagulation & Fibrinolysis","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143967373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Haploidentical stem cell transplantation in DOCK8 deficiency: a case report of successful outcomes.","authors":"Sondus Alsharidah, Ahmed Elhussein, Waleed Al-Herz","doi":"10.1097/MBC.0000000000001351","DOIUrl":"https://doi.org/10.1097/MBC.0000000000001351","url":null,"abstract":"<p><p>DOCK8 deficiency syndrome, formerly known as autosomal recessive hyper-IgE syndrome (AR-HIES), is a rare combined immunodeficiency disorder characterized by recurrent infections, eczema, eosinophilia, and elevated immunoglobulin E (IgE) levels. We present a case of a 6-year-old girl with DOCK8 deficiency syndrome, who experienced recurrent skin infections and molluscum contagiosum since infancy. Genetic testing confirmed the diagnosis. Due to the high morbidity and mortality associated with DOCK8 deficiency syndrome, she underwent hematopoietic stem cell transplantation (HSCT) from her father. Posttransplant, the patient's skin condition significantly improved, and she achieved full donor chimerism. This case highlights the importance of considering DOCK8 deficiency in patients with recurrent infections, eczema, eosinophilia, and high IgE levels, and the potential curative effect of HSCT for these patients.</p>","PeriodicalId":8992,"journal":{"name":"Blood Coagulation & Fibrinolysis","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143964646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of intrauterine growth on coagulation and factor XII function in preterm infants.","authors":"Şükran Yildirim, Asuman Çoban, Ayşegül Ünüvar, Zeynep İnce","doi":"10.1097/MBC.0000000000001361","DOIUrl":"https://doi.org/10.1097/MBC.0000000000001361","url":null,"abstract":"<p><p>This study aims to examine the impact of intrauterine growth restriction (IUGR) on coagulation in preterm newborns and assess the administration of fresh frozen plasma. The study involved 30 preterm infants with IUGR and 32 preterm infants without it. Blood samples were collected within 4 h after birth to analyze blood gases, complete blood counts, renal and liver function tests, and coagulation factors. Differences between the two groups were assessed using SPSS version 15. IUGR significantly impacts coagulation in infants born before the 32nd week of gestation. Preterm infants with IUGR, specifically those born before 32 weeks, show notably lower levels of coagulation factors V, VII, XIII, and antithrombin III. Additionally, they have higher levels of factor VIII and longer thromboplastin times. The coagulation effects are less pronounced in infants born at or after 32 weeks of gestation than those born before 32 weeks. Moreover, factor XII levels are significantly higher in all preterm infants with IUGR. Preterm infants with intraventricular hemorrhage have prolonged prothrombin time and activated partial thromboplastin time, and their coagulation factor levels differ significantly. Conventional coagulation tests may not reliably predict bleeding tendencies in preterm infants with IUGR. However, these tests help assess the risk of intraventricular hemorrhage in preterm babies. Infants born before 32 weeks of gestation often have lower levels of coagulation factors because of growth restriction, which makes the administration of fresh frozen plasma a reasonable option in cases of bleeding for this population. Additionally, factor XII levels may provide insight into conditions related to hypoxia and inflammation, including IUGR.</p>","PeriodicalId":8992,"journal":{"name":"Blood Coagulation & Fibrinolysis","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143969493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}